Skip to content
Studies have shown that active fund managers routinely underperform the S&P500 index*
Home
Articles
WALL STREET X
Forecasts
Portfolios
Wall Street X
Articles
Forecasts
Portfolios
Search
Results for
{phrase}
(
{results_count}
of
{results_count_total}
)
Displaying
{results_count}
results of
{results_count_total}
Humacyte, Inc. (NASDAQ: HUMA)
HUMA Stock Predictions and Ratings
WSX Rating:
STRONG BUY
WSX Forecast (1yr):
157.30%
Analyst Rating:
STRONG BUY
Analyst Forecast (1yr):
155%
HUMA Stock Analysis
HUMA
PE Ratio:
HUMA
PEG Ratio:
Not Available
HUMA
Forward EPS Growth (12 month):
0.00%
HUMA
PS Ratio:
116.7
HUMA
PSG Ratio:
0.5
HUMA
Forward Revenue Growth (12 month):
228.90%
HUMA Articles
No data was found